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Background: Although the prognostic roles of β-catenin expression in non-small cell lung cancer (NSCLC) have been
reported in several immunohistochemical (IHC) studies, the results were not consistent because some studies lack
sufficient number of the positive cases or did not evaluate the subcellular localization features of the protein.
Method: In this study, we have evaluated the expression levels and subcellular localization of β-catenin and Nanog
proteins IHC staining in tissue specimens from 309 patients with NSCLC, and explored their association with
clinicopathological features and patient outcome.
Results: We showed that patients with negative expression of membranous beta-catenin had a trend towards shorter
survival (p=0.064) than those with positive expression. In contrast to previous studies, we found that increased
expression of either cytoplasmic or nuclear β-catenin was strongly associated with poor prognosis and was an
independent prognosticator for overall survival (p <0.01). We further found that NSCLC cells frequently exhibited an
abundance of nuclear Nanog protein which was significantly correlated with nuclear β-catenin expression (p <0.01)
and poor prognosis (p <0.01). Interestingly, immunofluorescent staining results revealed that increased expression of
Nanog and nuclear translocation of β-catenin occurred concomitantly in response to epidermal growth factor receptor
(EGFR) signaling in A549 and H23 cells. Furthermore, western blot analysis show that nuclear β-catenin rather than
cytoplasmic β-catenin expression in the A549 and H23 cells can be enhanced by adding EGF, Nanog expression in the
A549 and H23 cells with knockdown of β-catenin can not be obviously enhanced by adding EGF.
Conclusion: We propose that evaluation of subcellular localization of β-catenin and Nanog expression is of clinical
significance for patients with NSCLC.
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Lung cancer is the most common cancer worldwide,
and has the highest incidence and mortality levels
of any cancer [1]. NSCLC is thought to originate in
lung epithelial cells, and comprises diverse histological
subtypes including adenocarcinoma, bronchioloalveo-
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reproduction in any medium, provided the orand approximately 85% of lung cancers are identified as
NSCLC [2]. Advances in surgical, radiotherapeutic, and
chemotherapeutic approaches have been made, but the
long-term survival rate remains low [3], with a 5-year
overall survival of 9-15% and a median survival time of
16 to 18 months [4]. The aggressive and heterogeneous
nature of lung cancer has thwarted efforts to reduce
mortality from the NSCLC. Thus, there is an urgent
need for the determination of useful prognostic mo-
lecular markers for clinical management of patients
with NSCLC.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathway that plays pivotal roles in pattern formation
during embryogenesis and in malignant transformation
[5]. At the plasma membrane, β-catenin is associated
with the cadherin class of cell-adhesion proteins and
functions in regulating cell adhesion [6]. In the absence
of Wnt signal, cytoplasmic β-catenin interacts with
glycogen synthase kinase-3β (GSK-3β) in a large com-
plex known as destruction complex which also contains
the adenomatous polyposis coli (APC) and the axis in-
hibition protein (Axin). Phosphorylation of β-catenin at
its N-terminus by GSK-3β leads to its degradation via
the ubiquitin/proteasome pathway. When Wnt pathway
is activated, β-catenin phosphorylation by GSK-3β is
inhibited. The hypophosphorylated β-catenin is stabi-
lized and translocated to the nucleus, where it binds
T-cell factor/lymphoid enhancer factor (TCF/Lef ) and
activates its target gene expression [7].
Nanog is a core transcription factor required for main-
tenance of the pluripotency and self-renewal of embry-
onic stem cells. Nanog protein has been identified asTable 1 Correlation between the clinicopathologic characteris
expression of β-catenin in 316 NSCLC patients
MEMBRANOUS(n, %) C
Variables Cases Low(102) High(207) pa L
Gender
Male 134 42(31.3) 92(68.7) 0.586 7
Female 175 60(34.3) 115(65.7) 1
Age (years)b
<52 149 59(39.6) 90(60.4) 0.017 8
≥52 160 43(26.9) 117(73.1) 9
Histologic subtype
Squamous carcinoma 142 47(33.1) 95(66.9) 0.976 8
Adenocarcinoma 167 55(32.9) 119(67.1) 8
Histologicalgrade
Grade 1 126 34(27.0) 92(73.0) 0.032 7
Grade 2 112 36(32.1) 76(67.9) 6
Grade 3 71 32(45.1) 39(54.9) 4
T classification
T1 71 23(32.4) 48(67.6) 0.069 4
T2 58 23(39.7) 35(60.3) 3
T3 126 39(31.0) 87(69.0) 7
T4 54 17(31.5) 37(68.5) 2
Clinical stage
I 108 35(32.4) 73(67.6) 0.818 6
II 81 29(35.8) 52(64.2) 4
III 120 38(31.7) 82(68.3) 6
a Chi-square test.
b Patients were divided according to the median values of age.one of four factors essential for reprogramming adult cells
into induced pluripotent stem (iPS) cells [8]. Recent
studies have revealed that Nanog is also involved in self-
renewal and tumorigenicity of cancer stem cells in a vari-
ety of human cancers [9-12]. Increased expression of
Nanog protein was observed in a panel of specimens of
lung adenocarcinoma and ectopic coexpression of Nanog
and another stem cell factor Oct4 enhanced tumor-
initiating ability, epithelial–mesenchymal transition, and
tumorigenesis in a lung cancer cell line [13].
Nanog is critically involved in regulation of cancer stem
cells in several types of tumors [9-12] and has been reported
to be target gene of β-catenin that inhibits differentiation by
increasing the expression of Nanog [14]. We also demon-
strated Nanog expression could be influenced by β-catenin
in nasopharyngeal carcinoma in our earlier study [15].
In this study, we have evaluated the expression levels
and subcellular localization of β-catenin and Nanog pro-
teins in primary tumor specimens from 309 patients
with NSCLC, and explored their association with clini-
copathological features and patient outcome.tics and membranous, cytoplasmic and nuclear
YTOPLASMIC(n, %) NUCLEAR(n, %)
ow(176) High(133) pa Low(170) High(139) pa
4(55.2) 60(44.8) 0.590 73(54.5) 61(45.5) 0.868
02(58.3) 73(41.7) 97(55.4) 78(44.6)
5(57.0) 64(43.0) 0.976 77(51.7) 72(48.3) 0.255
1(56.9) 69(43.1) 93(58.1) 67(41.9)
7(61.3) 55(38.7) 0.158 85(59.9) 57(40.1) 0.115
9(53.3) 78(46.7) 85(50.9) 82(49.1)
5(59.5) 51(40.5) 0.644 83(65.9) 43(34.1) 0.001
0(53.6) 52(46.4) 59(52.7) 53(47.3)
1(57.7) 30(42.3) 28(39.4) 43(60.6)
3(60.6) 28(39.4) 0.349 40(56.3) 31(43.7) 0.727
7(63.8) 21(36.2) 32(55.2) 26(44.8)
0(55.6) 56(44.4) 72(57.1) 54(42.9)
6(48.1) 28(51.9) 26(48.1) 28(51.9)
2(57.4) 46(42.6) 0.957 56(51.9) 52(48.1) 0.689
5(55.6) 36(44.4) 45(55.6) 36(44.4)
9(57.5) 51(42.5) 69(57.5) 51(42.5)
Table 2 The clinicopathologic characteristics of NANOG
expression in 316 NSCLC patients
NANOG(n, %)
Variables case Low(215) High(94) pa
Gender
Male 134 90(67.2) 44(32.8) 0.419
Female 175 125(71.4) 50(28.6)
Age (years)b
<52 149 99(66.4) 50(33.6) 0.248
≥52 160 116(72.5) 44(27.5)
Histologic subtype
Squamous carcinoma 142 103(72.5) 39(27.5) 0.298
Adenocarcinoma 167 112(67.1) 55(32.9)
Histologicalgrade
Grade 1 126 105(83.3) 21(16.7) <0.001
Grade 2 112 80(71.4) 32(28.6)
Grade 3 71 30(42.3) 41(57.7)
T classification
T1 71 50(70.4) 21(29.6) 0.572
T2 58 36(62.1) 22(37.9)
T3 126 91(72.2) 35(27.8)
T4 54 38(70.4) 16(29.6)
Clinical stage 0.358
I 108 75(69.4) 33(30.6)
II 81 61(75.3) 20(24.7)
III 120 79(65.8) 41(34.2)
a Chi-square test.
b Patients were divided according to the median values of age.
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Patients and tumor specimens
Primary tumor specimens from 309 NSCLC patients who
underwent curative surgical resection were evaluated in
this study. None of these patients had undergone chemo-
therapy or radiotherapy prior to the surgery. Of these pa-
tients, 203 were collected from 2001 to 2005 at Hunan
Tumor Hospital and the rest of 96 were from 2002 to 2006
at the Affiliated Hospital of Guilin Medicine University.
Patients in the study were examined and treated according
to provincial guidelines. This study was approved by the
Research Ethics Boards of the Southern Medical Univer-
sity, China.
Cores from formalin-fixed paraffin embedded tumor
tissues of NSCLC were arrayed in triplicate onto a tissue
microarray (TMA) and each TMA block consisted of up
to 40 tissue cores, before the area of cores were chosen,
the preliminary experiment of β-catenin were made to
ensure the typical cores. TMAs were constructed using
an automated tissue arrayer (Beecher Instruments Inc.
USA) by Auragene Bioscience Corporation, China. Tis-
sues core with a diameter of 3 mm was transferred to a
recipient paraffin block (array margin of 15mm×20 mm).
The block was sectioned at a series of 4-μm-thick slices.
Once the TMA slices were made, they were heat 60°C
for 1 h to aid cutting.
Relevant clinical pathologic features (Table 1) were
obtained from the patients’ files and/or by telephone in-
terviews with the patients or their relatives. Pathological
stages were classified according to the TNM staging sys-
tem. Histological grading and typing of the tumor were
determined according to the World Health Organization
tumor classification system.
Immunohistochemistry (IHC) staining
Serial tumor sections and IHC staining were used to
evaluate both β-catenin and Nanog proteins. β-catenin
immunoactivity was examined using a mouse polyclonal
antibody (Cell Signaling Technology, Danvers). Nanog
protein was detected with a rabbit polyclonal antibody
(Cell Signaling Technology, Danvers). The TMA blocks
containing tissue sections (4 μm) were de-waxed in
xylene, rehydrated through a graded series of ethanol so-
lutions, rinsed in distilled water for 5 min, and then
immersed in boiling citrate buffer in methanol for 1.5 min
for antigen retrieval. After deparaffinization and rehydra-
tion, blocks were incubated in 3% hydrogen peroxide to
block endogenous peroxidase activity. Then the sections
were subject to immunohistochemistry staining using the
primary antibodies overnight at 4°C in a humidity cham-
ber. The avidin-biotin technique was applied using DAB
for visualization and hematoxylin for nuclear counter-
staining. Negative controls were prepared by omitting the
primary antibody. Histological and IHC evaluation wereindependently performed by two pathologists without
knowledge of the clinicopathological outcomes of the
patients. We classified the IHC staining results into three
categories according to subcellular localization of β-catenin,
e.g. membranous, cytoplasmic and nuclear. Briefly, each
slide was examined in its entirety under a light microscope,
and an initial score was assigned which represented the
estimated proportion of positive tumor cells (0: ≤5%; 1:
5~25%; 2: 25~75%; 3: ≥75%). The score 0 was defined as
low and 1, 2, 3 as high. Slides with indeterminate evaluation
were re-evaluated, and a consensus was reached.
Immunofluorescent staining
For immunofluorescent staining, A549 [16] or H23 [17]
cells grown on the surface of cover slides were serum-
starved overnight followed by stimulation with 50 ng/ml
EGF for 24 hours. Cells were fixed with 4% paraformal-
dehyde, rehydrated in PBS, and incubated with mouse
anti-β-catenin (Santa Cruz Biotech) and rabbit anti-Nanog
primary antibodies (Cell Signaling Technology, Danvers)
at room temperature for 40 min. Subsequently, cells were
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body and Alexa Fluor 594-conjugated anti-mouse antibody
(Molecular Probes; Invitrogen Corp.) for 40 min at room
temperature. The nuclei were stained with DAPI. Slides
were examined with a fluorescent confocal microscope
(Olympus FV1000, Japan).
Western blot analysis
Cytoplasmic and nuclear proteins of A549 and H23 cells
were extracted by Nuclear and Cytoplasmic Protein Ex-
traction Kit (Beyotime), then equal amount of protein
were subjected to electrophoresis on a SDS-PAGE gel.
The separated proteins were transferred to PVDF mem-
branes (Millipore) and probed with appropriate primary
antibodies. Protein bands were detected by enhanced
chemiluminescence reagents (Pierce Biotechnology).Figure 1 IHC staining for β-catenin and Nanog expression in NSCLC. R
membrane (A), in cytoplasma (B) or in the nucleus (C and D). In serial sec
staining (C and D) in the nuclei of most cells.Lentiviral constructs and infection of NSCLC cells
Both pLKO.1 lentiviral shRNA vector and control shRNA
targeting against GFP were from Aldrich -Sigma. β-catenin
targeting sequences are GCTTGGAATGAGACTGCTG
AT, which was previously described in our earlier study
[15]. The sense and antisense oligonucleotides were
annealed and ligated into pLKO.1 lentiviral vector. The vi-
ruses were packaged in 293T cells according to standard
protocols. Viral production and infection of target cells
were previously described [18]. Infected cells were selected
with 2 μg/mL puromycin.
Statistical methods
Statistical analysis was performed using the SPSS 13.0
software package for Windows. Associations between
clinicopathological features and IHC β-catenin and Nanogepresentative images of intracellular β-catenin expressed at the
tions, Nanog staining (E and F) frequently overlapped with β-catenin
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Multivariate survival analyses were performed with the
Cox regression model. Overall survival (OS) was mea-
sured from the onset of treatment to the date of death or
the survival status at the last date of follow-up. OS prob-
abilities were estimated by the Kaplan-Meier method
and the significance of differences was assessed by the log-
rank test. Correlations between β-catenin and Nanog ex-
pression with clinicopathological factors were analyzed
using Fisher’s exact probability test or the chi-squared test.
A p-value < 0.05 was considered statistically significant.
Results
Clinicopathological features
Tumor specimen from 309 NSCLC patients consisting
of 134 males and 175 female were included in this study.
The median age was 52 years (range: 37–82 years). Of
these patients, 167 (32.9%) were diagnosed as adeno-
carcinoma and 142 (33.1%) diagnosed as squamous car-
cinoma. Clinical stages, histological grades, and studied
proteins were correlated as shown in Table 1. The tumor
tissues was classified in three histological grades: grade 1
(126 patients), grade 2 (112 patients) and grade 3 (71 pa-
tients). The expression of membranous and nuclear, but
not cytoplasmic, β-catenin expression were correlated with
the histological grade (p<0.05), as shown in Table 1. Nanog
expression that was localized in the nucleus was also cor-
related with the histological grade (p <0.01, Table 2).
Expression of β-catenin in NSCLC
Representative images of β-catenin immunohistochemi-
cal staining in NSCLC tissues are shown in Figure 1A-C.
Positive membranous, cytoplasmic, and nuclear expres-
sion of β-catenin was detected in 67.0% (207/309), 43.0%
(133/309), and 45.0% (139/309) of the NSCLC tissues,
respectively.
Nanog is critically involved in regulation of cancer stem
cells in several types of tumors and has been reported to
be transcriptionally regulated by β-catenin. Thus weFigure 2 The Kaplan-Meier analysis of survival rate of patients accord
membranous (A), cytoplasmic (B), and nuclear (C) β-catenin expression onfurther examined Nanog expression in NSCLC specimen.
We found that 30.4% (94/309) tumor tissues displayed
Nanog immunoactivity that was located in the nucleus in
most cases (Figure 1D).Follow-up outcome
The last follow-up date is Sep. 29th, 2009, with a median
follow-up time 52 months (range 7–69.5 months). The
1-, 3- and 5-year overall survival (OS) rates were 82.4%,
52.5%, 30.6%, respectively. The survival rates of 309
NSCLC patients according to status of β-catenin and
Nanog were shown in Table 2. The survival rate of pa-
tients with nuclear β-catenin expression was significantly
lower than that of patients without nuclear β-catenin ex-
pression (p <0.01, Figure 2C). Likewise, the survival rate
of patients with cytoplasmic β-catenin expression was
significantly lower than that of patients without cytoplas-
mic β-catenin expression (p <0.01, Figure 2B). However,
there was no statistical difference in the survival rate be-
tween patients with or without membranous β-catenin
(p=0.064, Figure 2A), but with a trend toward reduced
survival in patients with loss of β-catenin expression. Pa-
tients without Nanog protein expression had a signifi-
cantly better prognosis and longer survival. The overall
survival rate was 12.3% (Nanog-positive) and 38.3%
(Nanog-negative) for this group (p <0.01) (Figure 3).
Univariate analyses showed no significant association
between OS and age (>52 yr vs. ≤52 yr), sex (female vs.
male), histological subtype (adenocarcinoma vs. squamous
carcinoma), T stage (T3-T4 vs. T1-T2), clinical stage (stage
III vs. I-II) (Table 3). The expression levels of cytoplasmic
and nuclear β-catenin and Nanog were an independent
prognosticator for OS (Table 3). In a multivariate analysis
incorporating all clinicopathologic variables and covariates
as shown in Table 3, comparisons between genders ages,
tumor grades, tumor T stages, tumor C stages, expression
levels of Nanog protein (low vs. high), and intracellular β-
catenin protein expression at the membrane, in cytoplasming to status of β-catenin expression. The influence of

















Figure 3 The Kaplan-Meier analysis of survival rate of patients according to status of Nanog expression.
Table 3 Univariate and multivariate analysis for clinicopathologic variables
Univariate analysis Multivariate analysis
Parameters HRa 95% CIb Pc HRa 95% CIb Pc
Gender
Male vs. female 1.032 0.782-1.363 0.826
Age (years)
<52 vs.≥52 0.995 0.756-1.311 0.948
Histologic subtype
ad vs l 1.111 0.842-1.466 0.456
T classification
T1–T2 vs. T3–T4 0.956 0.832-1.099 0.529
C classification
I-II vs. III 0.961 0.818-1.129 0.629
Differention
Grade1,Grade2,Grade3 1.520 1.272-1.816 0.000 1.526 1.273-1.829 0.000
Membranous
positive and negative 0.763 0.571-1.021 0.069 0.820 0.609-1.106 0.193
Cytoplasmic
positive and negative 1.815 1.375-2.396 0.000 1.871 1.412-2.478 0.000
Nuclear
positive and negative 3.864 2.872-5.200 0.000 3.776 2.786-5.118 0.000
Nanog
positive and negative 1.994 1.494-2.661 0.000 1.700 1.249-2.315 0.001
a HR Harzard Rate.
b CI Confidence Interval.
c Cox regression model.
The expression levels of cytoplasmic and nuclear β-catenin and Nanog were an independent prognosticator for overall survive.
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Membranous 102 - 63(61.8) 39(38.2) 0.036
207 + 152(73.4) 55(26.6)
Cytoplasmic 176 - 128(72.7) 48(27.3) 0.166
133 + 87(65.4) 46(34.6)
Nuclear 170 - 148(87.1) 22(12.9) <0.001
139 + 67(48.2) 72(51.8)
a Chi-square test.
Nanog is significantly associated with membranous or nuclear β-catenin
expression (p <0.05). No statistical correlation exists between cytoplasmic
β-catenin and Nanog proteins(p=0.166).




Cytoplasmic 176 - 142(80.7) 34(19.3) <0.001
133 + 28(21.1) 105(78.9)
a Chi-square test.
Cytoplasmic β-catenin is significantly associated with Nuclear β-catenin
expression (p <0.001).
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tify independent prognostic factors.
Correlation between β-catenin and Nanog expression
in NSCLC
We further analyzed correlation between expression
status of Nanog and β-catenin. As mentioned above,
positive Nanog protein staining was almost exclusively
observed in nucleus and β-catenin expression was strati-
fied according to its subcellular locations (Table 4). Sev-
enty two of the 139 (51.8%) tumor tissues that stained
positive for nuclear β-catenin also displayed Nanog
immunoactivity. Among the 170 specimen without nu-
clear β-catenin expression, only 22 (12.94%) showed
Nanog immunoreactions (Fig. 4C, p < 0.001). On the
contrary, only 55 (26.6%) of the 207 specimen with
membranous β-catenin expression showed Nanog
immunoreactions (Table 4, p = 0.036). Likewise, cyto-
plasmic β-catenin expression is not correlated with
Nanog protein (Table 4, p = 0.166) even though cytoplas-
mic β-catenin is associated with poor prognosis. However,
expression of cytoplasmic and nuclear β-catenin is corre-
lated, among the 133 specimen with cytoplasmic β-catenin
expression, 105 (78.9%) showed nuclear β-catenin
immunoreactions (Table 5, p < 0.001).
Expression of β-catenin and Nanog was concomitantly
regulated by EGFR signaling
EGFR signal transduction pathway is critically involved
in cell proliferation and survival of tumors of epithelial
cell origin [19]. Increased expression of EGFR has been
detected in 40%–80% of NSCLC and has been associated
with advanced disease and poor prognosis [20]. Recently,
we demonstrated that activation of EGFR increased can-
cer stem-like cell properties in nasopharyngeal carci-
noma, and this effect of EGFR was mediated by PI3K/
AKT/β-catenin signaling [15]. In the present study, high
incident of nuclear β-catenin was detected in lung can-
cer specimens and was associated with poor survival.
Thus we asked if EGFR signaling could induce β-catenin
activation in NSCLC. For this purpose, serum-starved
A549 (Figure 4A) or H23 (Figure 4B) cells were incubated
without or with EGF and subjected to immunofluorescent
staining. In the absence of EGF, β-catenin was located pre-
dominantly at the plasma membrane, with faint staining
distributed in the cytoplasm. When cells were treated with
EGF, β-catenin staining translocated to the nucleus in both
A549 and H23 cells. These results suggested that nuclear
accumulation of β-catenin can be induced not only by
Wnt signaling, but also by EGF stimulation in NSCLC. In
addition, nuclear Nanog expression was dramatically en-
hanced in response to EGFR activation. These results of
in vitro experiments with established cell lines are consist-
ent with our finding that nuclear β-catenin is significantlyassociated with Nanog expression in primary NSCLC
specimens.Nuclear β-catenin is requirement in the regulation of Nanog
We investigated the requirement of β-catenin in the regu-
lation of Nanog in A549 and H23. To this end, β-catenin
was knocked down with lentivirus-mediated shRNAs
(Figure 5A). Compared with cells infected with the con-
trol shRNA lentivirus, cells infected with β-catenin
shRNA lentivirus exhibited reduced Nanog expression.
Moreover, Nanog expression in the NSCLC cells with
knockdown of β-catenin can not be obviously enhanced
by adding EGF, but on the other hand, when the ex-
pression of β-catenin is increased by adding EGF,
Nanog thereupon increased expression upon β-catenin
(Figure 5B). It is worthy of note that nuclear β-catenin
rather than cytoplasm β-catenin expression in the
NSCLC cells can be enhanced by adding EGF, (Figure 5C).Discussion
During the past decade, mounting evidence has well
demonstrated that accumulation and nuclear localization
is a hallmark of Wnt/β-catenin pathway activation. In ad-
dition to controlling cell-cell adhesion through its bind-
ing with cadherin at the membrane, β-catenin acts as a
transcriptional activator in the nucleus where it interacts
with LEF1 and TCF transcription factors and regulates tran-
scription of target genes responsible for cell proliferation and
Figure 4 Expression of β-catenin and Nanog was concomitantly regulated by EGFR signaling. A549 (A) and H23 (B) cells were treated
without or with EGF followed by immunofluorescent staining. In the absence of EGF, β-catenin was located predominantly at the plasma
membrane, with faint staining distributed in the cytoplasm. Faint Nanog staining was detected in the nucleus. When cells were treated with EGF,
β-catenin staining translocated to the nucleus in both cell lines and nuclear Nanog staining was moderately increased in A549 cells and
abundantly accumulated in H23 cells.
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from cell membrane to the nucleus determines its two
distinct functions. In agreement with these findings, cyto-
plasmic and nuclear β-catenin expression has been
reported to be associated with a poorer prognosis in pa-
tients with cancers of breast, liver, and colon [21-23].
The prognostic roles of β-catenin expression in
NSCLC have been extensively studied in the past years
[24,25]. In a very recent study reported by Chiu et al. on
370 cases of NSCLC, β-catenin expression was found to
be negative in 28% of tumors and positive in 72% of tu-
mors. The lack of β-catenin expression was significantly
associated with poor survival and retained independent
prognostic significance [26]. Similar results were alsoobserved in a number of early studies. In the present
study, we evaluated the expression of β-catenin in 309
tissue specimens of NSCLC. In order to more precisely
analyze IHC results in relation to patient prognosis and
survival, we have classified the IHC staining results into
three categories according to subcellular localization of
β-catenin. We showed that patients with negative ex-
pression of membranous β-catenin had a trend of
shorter survival (p = 0.067) than those with positive ex-
pression. This result is in agreement with the findings
reported by others previously.
In addition to the similarity, there are some striking
differences between our results and those of earlier stu-
dies. We found that increased expression of nuclear
Figure 5 Nuclear β-catenin is requirement in the regulation of Nanog. A549 cells and H23 cells infected with control shRNA lentivirus(Cont)
or β-catenin shRNA(sh). In both cell lines, β-catenin protein was markedly knocked down with β-catenin shRNA. Knockdown of β-catenin also
decreased the Nanog expression. All experiments were carried 3 times independently (Figure 5A). Nanog expression in the A549 and H23 cells
with knockdown of β-catenin can not be obviously enhanced by adding EGF, but on the other hand, when the expression of β-catenin is
increased by adding EGF, Nanog thereupon increased expression upon β-catenin (Figure 5B). Nuclear β-catenin(Nucles) rather than cytoplasm
β-catenin(Cyto) expression in the A549 and H23 cells can be enhanced by adding EGF (Figure 5C).
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patients with NSCLCs. In addition, multivariate analysis re-
vealed that the expression of nuclear β-catenin was an in-
dependent prognosticator for OS. These data are consistent
with recent observations that increased Wnt/β-catenin
pathway activity is associated with metastasis and re-
lapse in primary lung adenocarcinoma [27]. Importantly,
even though we revealed that cytoplasmic β-catenin was a
prognosticator, these observations do not exclude the pos-
sibility that nuclear β-catenin acts primarily on the prog-
nosis, since a majority of cases over expressing cyto-plasmic
β-catenin also contain nuclear β-catenin expression. We fur-
ther demonstrated by immunofluorescent staining and/or
western blot analysis that independent to Wnt, nuclearaccumulation of β-catenin can be induced by EGFR path-
way that is critically involved in tumorigenesis of NSCLC.
Our in vitro results provide not only supportive evidence
to our IHC finding that nuclear β-catenin is signifi-
cantly associated with Nanog expression in primary
NSCLC specimens, but also an additional mechanism by
which β-catenin activation is regulated by growth factor
signaling in a Wnt-independent manner in NSCLC.
In contrast to our investigation, some earlier studies eval-
uated only the overall intensity of IHC staining of β-catenin
in tumor cells without stratification of the data based on
subcellular localization of the protein. Thus the distinct
impact of β-catenin at different cellular compartments on
patient prognosis and survival was ignored. Some of the
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specifically, but found no correlation between cytoplasmic
or nuclear staining and clinicopathological parameters or
survival rates, probably due to low numbers of the positive
cases identified in those studies. One of the early study [30]
showed that increased expression of cytoplasmic and nu-
clear β-catenin can predict favorable prognosis of NSCLCs
patients. However, β-catenin immunoactivity was found to
be associated with increased proliferation as suggested by
high Ki-67 expression in the same set of specimens.
Nanog protein is elevated in many human tumors in-
cluding NSCLC and might positively regulate tumor me-
tastasis through enhancing EMT in lung adenocarcinoma
[13]. We found that Nanog is expressed in significant por-
tion of specimens and Nanog immunoactivity was ob-
served in the nucleus. Expression of Nanog is significantly
correlated with nuclear, but not membranous nor cyto-
plasmic, β-catenin. Furthermore, our IHC staining dem-
onstrated that increased expression of Nanog and nuclear
translocation of β-catenin occurred concomitantly in re-
sponse to EGFR signaling in A549 and H23 lung adeno-
carcinoma cells. This correlation is in agreement with a
previous report demonstrating that β-catenin up-regulates
Nanog expression in embryonic stem cells [31]. We pro-
posed that Nanog contributes to tumorigenesis and repre-
sents an important prognostic marker of poor prognosis
in patients with NSCLC.
Taken together, we showed that negative expression of
membranous β-catenin correlated with a shorter survival
time than the normal expression level of the protein. How-
ever, high expression of nuclear β-catenin was strongly
associated with poor prognosis and was an independent
prognosticator for OS. We further found that NSCLC cells
frequently exhibited nuclear Nanog protein abundance
that is significantly correlated with nuclear β-catenin ex-
pression and poor prognosis. Furthermore, results from
IHC staining with established lung cancer cell lines re-
vealed that increased expression of Nanog and nuclear
translocation of β-catenin occurred concomitantly in re-
sponse to EGFR signaling. In conclusion, we propose that
evaluation of subcellular localization of β-catenin and
Nanog expression is of clinical significance for patients
with NSCLC.Competing interests
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